New GH-1 gene mutations: Expanding the spectrum of causes of isolated growth hormone deficiency

Journal of Pediatric Endocrinology and Metabolism

Volumn 15, Issue SUPPL. 5, 2002, Pages 1301-1310

  Mullis, Primus E ^a   Deladoëy, Johnny ^a   Dannies, Priscilla S ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GH 1 gene; Growth hormone; Hormone deficiency; Isolated growth

Indexed keywords

DNA; GROWTH HORMONE; RNA;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CONSANGUINITY; FAMILIAL DISEASE; FREQUENCY ANALYSIS; GENE MUTATION; GENETIC ANALYSIS; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEREDITY; HORMONE INHIBITION; HUMAN; PATHOGENESIS; PHENOTYPE; X CHROMOSOME LINKAGE;

HUMAN GROWTH HORMONE; HUMANS; MUTATION; PROTEIN FOLDING;

EID: 0036918610     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Phillips JA III. Inherited defects in growth hormone synthesis and action. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 7th Ed. New York, NY: McGraw-Hill, 1995; 3023-3044.
2. Vimpani GV, Vimpani AF, Lidgard GP, Cameron EH, Farquhar JW. Prevalence of severe growth hormone deficiency. Br Med J 1977; 2: 427-430.
3. Lacey KA, Parkin JM. Causes of short stature. A community study of children in Newcastle upon Tyne. Lancet 1974; i: 42-45.
4. Rona RJ, Tanner JM. Aetiology of idiopathic growth hormone deficiency in England and Wales. Arch Dis Child 1977; 52: 197-208.
5. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah Growth Study: Growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994; 125: 29-35.
6. Wagner JK, Eblé A, Hindmarsh PC, Mullis PE. Prevalence of human GH-1 gene alterations in patients with isolated growth hormone deficiency. Pediatr Res 1996; 43: 105-110.
7. Illig R. Growth hormone antibodies in patients treated with different preparations of human growth hormone (HGH). J Clin Endocrinol Metab 1970; 31: 679-688.
8. Laron Z, Kelijman M, Pertzelan A, Keret R, Shoffner JM, Parks JS. Human growth hormone gene deletion without antibody formation or growth arrest during treatment-a new disease entity? Isr J Med Sci 1985; 21: 999-1006.
9. Mullis PE, Akinci A, Kanaka C, Eblé A, Brook CG. Prevalence of human growth hormone-1 gene deletions among patients with isolated growth hormone deficiency from different populations. Pediatr Res 1992; 31: 532-534.
10. Kamijo T, Phillips JA III, Ogawa M, Yuan L, Shi Y, Bao XL. Screening for growth hormone gene deletions in patients with isolated growth hormone deficiency. J Pediatr 1991; 118: 245-248.
11. Vnencak-Jones CL, Phillips JA III. Hot spots for growth hormone gene deletions in homologous regions outside Alu repeats. Science 1990; 250: 1745-1748.
12. Kuhlmann BV, Mullis PE. Genetics of the growth hormone axis. J Pediatr Endocrinol Metab 1997; 10: 161-174.
13. Fleisher TA, White RM, Broder S, Nissley SP, Blaese RM, Mulvihill JJ, Olive G, Waldmann TA. X-linked hypogammaglobulinemia and isolated growth hormone deficiency. N Engl J Med 1980; 302: 1429-1439.
14. Sitz KV, Burks AW, Williams LW, Kemp SF, Steele RW. Confirmation of X-linked hypogammaglobulinemia with isolated growth hormone deficiency as a disease entity. J Pediatr 1990; 116: 292-294.
15. Cogan JD, Phillips JA III, Schenkman SS, Milner RD, Sakati N. Familial growth hormone deficiency: a model of dominant and recessive mutations affecting a monomeric protein. J Clin Endocrinol Metab 1994; 79: 1261-1265.
16. Duquesnoy P, Simon D, Netchine I, Dastot F, Sobrier ML, Goossens M, Cernichow P, Amselem S. Familial isolated growth hormone deficiency with slight height reduction due to a heterozygote mutation in GH gene. In: 80th Annual Meeting of the Endocrine Society, 1998; Abst P2-20217.
17. Moseley CT, Mullis PE, Prince MA, Phillips JA III. An exon splice enhancer mutation causes autosomal dominant GH deficiency. J Clin Endocrinol Metab 2002; 87: 847-852.
18. Wajnrajch MP, Gertner JM, Mullis PE, Deladoëy J, Cogan JD, Lekhakula S, Kim S, Dannies PS, Saenger P, Moshang T, Phillips JA III, Leibel RL. Arg183His, a new mutational "hot-spot" in the growth hormone (GH) gene causing isolated GH deficiency type II. J Endocr Genet 2000; 1: 125-135.
19. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255: 306-312.
20. Cunningham BC, Ultsch M, de Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991; 254: 821-825.
21. Arnold A, Horst SA, Gardella TJ, Baba H, Levine MA, Kronenberg HM. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990; 86: 1084-1087.
22. Ito M, Jameson JL, Ito M. Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. J Clin Invest 1997; 99: 1897-1905.
23. Arrandale JM, Dannies PS. Inhibition of rat prolactin (PRL) storage by coexpression of human PRL. Mol Endocrinol 1994; 8: 1083-1090.
24. Binder G, Brown M, Parks JS. Mechanisms responsible for dominant expression of human growth hormone mutations. J Clin Endocrinol Metab 1996; 81: 4047-4050.
25. Lee MS, Wajnrajch MP, Kim SS, Plotnick LP, Wang J, Gertner JM, Leibel RL, Dannies PS. Autosomal dominant growth hormone (GH) deficiency type II: the de132-71-GH deletion mutant suppresses secretion of the wild-type GH. Endocrinology 2000; 141: 883-890.
26. Deladoëy J, Stocker P, Mullis PE. Autosomal dominant GH deficiency due to an Arg183His GH-1 gene mutation: clinical and molecular evidence of impaired regulated GH secretion. J Clin Endocrinol Metab 2001; 86: 3941-3947.
27. Graves TK, Patel S, Dannies PS, Hinkle PM. Misfolded growth hormone causes fragmentation of the Golgi apparatus and disrupts endoplasmic reticulum-to-Golgi traffic. J Cell Sci 2001; 114: 3685-3694.
28. 2+. Mol Endocrinol 1997; 11: 1544-1551.
29. Procter AM, Phillips JA III, Cooper DN. The molecular genetics of growth hormone deficiency. Hum Genet 1998; 103: 255-272.
30. Hayashi Y, Kamijo T, Yamamoto M, Ohmori S, Phillips JA III, Ogawa M, Igarashi Y, Seo H. A novel mutation at the donor splice site of intron 3 of the GH-1 gene in a patient with isolated growth hormone deficiency. Growth Horm IGF Res 1999; 9: 434-437.
31. Kamijo T, Hayashi Y, Shimatsu A, Kinoshita E, Yoshimoto M, Ogawa M, Seo H. Mutations in intron 3 of GH-1 gene associated with isolated GH deficiency type II in three Japanese families. Clin Endocrinol (Oxf) 1999; 51: 355-360.
32. Kuznetsov G, Nigam SK. Folding of secretory and membrane proteins. N Engl J Med 1998; 339: 1688-1695.
33. Kim PS, Arvan P. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev 1998; 19: 173-202.
34. Cogan JD, Ramel B, Lehto M, Phillips J III, Prince M, Blizzard RM, de Ravel TJ, Brammert M, Groop L. A recurring dominant negative mutation causes autosomal dominant growth hormone deficiency-a clinical research center study. J Clin Endocrinol Metab 1995; 80: 3591-3595.
35. Missarelli C, Herrera L, Mericq V, Carvallo P. Two different 5′ splice site mutations in the growth hormone gene causing autosomal dominant growth hormone deficiency. Hum Genet 1997; 101: 113-117.
36. Binder G, Ranke MB. Screening for growth hormone (GH) gene splice-site mutations in sporadic cases with severe isolated GH deficiency using ectopic transcript analysis. J Clin Endocrinol Metab 1995; 80: 1247-1252.
37. Phillips JA III, Cogan JD. Genetic basis of endocrine disease. 6. Molecular basis of familial human growth hormone deficiency. J Clin Endocrinol Metab 1994; 78: 11-16.
38. Cogan JD, Prince MA, Lekhakula S, Bundey S, Futrakul A, McCarthy EM, Phillips JA III. A novel mechanism of aberrant pre-mRNA splicing in humans. Hum Mol Genet 1997; 6: 909-912.
39. McCarthy EM, Phillips JA III. Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA. Hum Mol Genet 1998; 7: 1491-1496.
40. Igarashi Y, Ogawa M, Kamijo T, Iwatani N, Nishi Y, Kohno H, Masumura T, Koga J. A new mutation causing inherited growth hormone deficiency: a compound heterozygote of a 6.7 kb deletion and a two base deletion in the third exon of the GH-1 gene. Hum Mol Genet 1993; 2: 1073-1074.
41. Lykke-Andersen J, Shu MD, Steitz JA. Human Upf proteins target an mRNA for nonsense-mediated decay when bound downstream of a termination codon. Cell 2000; 103: 1121-1131.
42. Muhlrad D, Parker R. Aberrant mRNAs with extended 3′ UTRs are substrates for rapid degradation by mRNA surveillance. RNA 1999; 5: 1299-1307.
43. Lee MS, Zhu YL, Chang JE, Dannies PS. Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells. J Biol Chem 2001; 276: 715-721.
44. Cunningham BC, Mulkerrin MG, Wells JA. Dimerization of human growth hormone by zinc. Science 1991; 253: 545-548.
45. Hayashi Y, Yamamoto M, Ohmori S, Kamijo T, Ogawa M, Seo H. Inhibition of growth hormone (GH) secretion by a mutant GH-I gene product in neuroendocrine cells containing secretory granules: an implication for isolated GH deficiency inherited in an autosomal dominant manner. J Clin Endocrinol Metab 1999; 84: 2134-2139.
46. Dannies PS. Protein hormone storage in secretory granules: mechanisms for concentration and sorting. Endocr Rev 1999; 20: 3-21.
47. Dannies PS. Protein folding and deficiencies caused by dominant-negative mutants of hormones. Vitam Horm 2000; 58: 1-26.
48. Dannies PS. Concentrating hormones into secretory granules: layers of control. Mol Cell Endocrinol 2001; 177: 87-93.
49. Sferra TJ, Collins FS. The molecular biology of cystic fibrosis. Annu Rev Med 1993; 44: 133-144.
50. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357: 605-607.
51. Chessler SD, Byers PH. BiP binds type I procollagen pro alpha chains with mutations in the carboxyl-terminal propeptide synthesized by cells from patients with osteogenesis imperfecta. J Biol Chem 1993; 268: 18226-18233.
52. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21.
53. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999; 50: 57-74.
54. Arnold J, Dawson S, Fergusson J, Lowe J, Landon M, Mayer RJ. Ubiquitin and its role in neurodegeneration. Prog Brain Res 1998; 117: 23-34.
55. Hurtley SM, Helenius A. Protein oligomerization in the endoplasmic reticulum. Annu Rev Cell Biol 1989; 5: 277-307.
56. Ellgard L, Molinari M, Helenius A. Setting the standards: quality control in the secretory pathway. Science 1999; 286: 1882-1888.
57. Wickner S, Maurizi MR, Gottesman S. Posttranslational quality control: folding, refolding and degrading proteins. Science 1999; 286: 1888-1893.
58. Thomas PJ, Qu BH, Pedersen PL. Defective protein folding as a basis of human disease. Trends Biochem Sci 1995; 20: 456-459.